1. Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland
2. Inserm, Unité Mixte de Recherche (UMR) 1231, Université de Bourgogne-Franche Comté, Dijon, France
3. NIBR, Cambridge, MA, USA
4. School of Medicine, Jacqui Wood Cancer Centre, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
5. Innovative Medicines Initiative MARCAR Consortium (http://www.imi-marcar.eu/index.php)
6. Department of Toxicology, University of Tübingen, Tübingen, Germany